La traduction de cette page est expérimentale et en cours de développement. N'hésitez pas à vos !
Clinuvel Pharmaceuticals Résultats passés
Passé contrôle des critères 3/6
Clinuvel Pharmaceuticals has been growing earnings at an average annual rate of 14.4%, while the Biotechs industry saw earnings growing at 13.5% annually. Revenues have been growing at an average rate of 23.9% per year. Clinuvel Pharmaceuticals's return on equity is 16.9%, and it has net margins of 36.9%.
Informations clés
14.4%
Taux de croissance des bénéfices
13.8%
Taux de croissance du BPA
Biotechs Croissance de l'industrie | 9.6% |
Taux de croissance des recettes | 23.9% |
Rendement des fonds propres | 16.9% |
Marge nette | 36.9% |
Prochaine mise à jour des résultats | 29 Aug 2024 |
Mises à jour récentes des performances passées
Recent updates
If EPS Growth Is Important To You, Clinuvel Pharmaceuticals (ASX:CUV) Presents An Opportunity
Aug 11Calculating The Intrinsic Value Of Clinuvel Pharmaceuticals Limited (ASX:CUV)
Jun 27Is Now The Time To Put Clinuvel Pharmaceuticals (ASX:CUV) On Your Watchlist?
May 09Estimating The Intrinsic Value Of Clinuvel Pharmaceuticals Limited (ASX:CUV)
Mar 24An Intrinsic Calculation For Clinuvel Pharmaceuticals Limited (ASX:CUV) Suggests It's 41% Undervalued
Nov 18Increases to Clinuvel Pharmaceuticals Limited's (ASX:CUV) CEO Compensation Might Cool off for now
Oct 20Is Clinuvel Pharmaceuticals Limited (ASX:CUV) Trading At A 21% Discount?
Jul 30Clinuvel Pharmaceuticals Limited (ASX:CUV) Shares Could Be 27% Below Their Intrinsic Value Estimate
Feb 27Does Clinuvel Pharmaceuticals (ASX:CUV) Deserve A Spot On Your Watchlist?
Dec 14This Is The Reason Why We Think Clinuvel Pharmaceuticals Limited's (ASX:CUV) CEO Might Be Underpaid
Nov 03A Look At The Fair Value Of Clinuvel Pharmaceuticals Limited (ASX:CUV)
Sep 23Here's Why I Think Clinuvel Pharmaceuticals (ASX:CUV) Might Deserve Your Attention Today
Jul 23With EPS Growth And More, Clinuvel Pharmaceuticals (ASX:CUV) Is Interesting
Apr 10Have Insiders Sold Clinuvel Pharmaceuticals Limited (ASX:CUV) Shares Recently?
Mar 06Earnings Miss: Clinuvel Pharmaceuticals Limited Missed EPS By 41% And Analysts Are Revising Their Forecasts
Feb 27What Is The Ownership Structure Like For Clinuvel Pharmaceuticals Limited (ASX:CUV)?
Feb 20Clinuvel Pharmaceuticals (ASX:CUV) Shareholders Have Enjoyed A Whopping 648% Share Price Gain
Feb 01Estimating The Fair Value Of Clinuvel Pharmaceuticals Limited (ASX:CUV)
Jan 14We Wouldn't Rely On Clinuvel Pharmaceuticals's (ASX:CUV) Statutory Earnings As A Guide
Dec 28Clinuvel Pharmaceuticals Limited's (ASX:CUV) Stock's On An Uptrend: Are Strong Financials Guiding The Market?
Dec 10What You Need To Know About Clinuvel Pharmaceuticals Limited's (ASX:CUV) Investor Composition
Nov 21Ventilation des recettes et des dépenses
Comment Clinuvel Pharmaceuticals gagne et dépense de l'argent. Sur la base des derniers bénéfices déclarés, sur une base LTM.
Historique des gains et des recettes
Date | Recettes | Les revenus | Dépenses G+A | Dépenses de R&D |
---|---|---|---|---|
31 Dec 23 | 82 | 30 | 29 | 1 |
30 Sep 23 | 80 | 30 | 27 | 1 |
30 Jun 23 | 78 | 31 | 25 | 1 |
31 Mar 23 | 74 | 29 | 23 | 1 |
31 Dec 22 | 70 | 26 | 21 | 1 |
30 Sep 22 | 68 | 24 | 20 | 1 |
30 Jun 22 | 66 | 21 | 19 | 1 |
31 Mar 22 | 62 | 22 | 18 | 1 |
31 Dec 21 | 57 | 24 | 17 | 1 |
30 Sep 21 | 53 | 24 | 16 | 1 |
30 Jun 21 | 48 | 25 | 14 | 1 |
31 Mar 21 | 43 | 23 | 14 | -1 |
31 Dec 20 | 38 | 21 | 14 | -3 |
30 Sep 20 | 35 | 18 | 13 | -1 |
30 Jun 20 | 33 | 15 | 12 | 0 |
31 Mar 20 | 32 | 15 | 10 | 4 |
31 Dec 19 | 32 | 15 | 8 | 8 |
30 Sep 19 | 32 | 16 | 7 | 7 |
30 Jun 19 | 31 | 18 | 6 | 7 |
31 Mar 19 | 29 | 17 | 6 | 7 |
31 Dec 18 | 27 | 16 | 6 | 6 |
30 Sep 18 | 26 | 15 | 6 | 6 |
30 Jun 18 | 25 | 13 | 6 | 6 |
31 Mar 18 | 21 | 10 | 6 | 5 |
31 Dec 17 | 17 | 6 | 6 | 5 |
30 Sep 17 | 17 | 7 | 6 | 4 |
30 Jun 17 | 17 | 7 | 5 | 4 |
31 Mar 17 | 14 | 5 | 5 | 4 |
31 Dec 16 | 12 | 3 | 4 | 4 |
30 Sep 16 | 9 | 0 | 4 | 4 |
30 Jun 16 | 7 | -3 | 5 | 4 |
31 Mar 16 | 5 | -5 | 3 | 3 |
31 Dec 15 | 4 | -6 | 2 | 3 |
30 Sep 15 | 4 | -8 | 4 | 3 |
30 Jun 15 | 3 | -10 | 6 | 3 |
31 Mar 15 | 3 | -10 | 8 | 3 |
31 Dec 14 | 3 | -10 | 9 | 3 |
30 Sep 14 | 3 | -8 | 7 | 3 |
30 Jun 14 | 3 | -6 | 5 | 3 |
31 Mar 14 | 3 | -6 | 5 | 3 |
31 Dec 13 | 2 | -6 | 5 | 3 |
30 Sep 13 | 2 | -6 | 5 | 4 |
Des revenus de qualité: CUV has high quality earnings.
Augmentation de la marge bénéficiaire: CUV's current net profit margins (36.9%) are lower than last year (37.6%).
Analyse des flux de trésorerie disponibles par rapport aux bénéfices
Analyse de la croissance passée des bénéfices
Tendance des revenus: CUV's earnings have grown by 14.4% per year over the past 5 years.
Accélération de la croissance: La croissance des bénéfices de CUV au cours de l'année écoulée ( 14.2% ) est inférieure à sa moyenne sur 5 ans ( 14.4% par an).
Bénéfices par rapport au secteur d'activité: La croissance des bénéfices CUV au cours de l'année écoulée ( 14.2% ) a dépassé celle du secteur Biotechs 1.1%.
Rendement des fonds propres
ROE élevé: CUV's Return on Equity (16.9%) is considered low.